FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma

Season 9 Episode 24  ·  Sep 07, 2023, 06:00 PM

Headliner
Share
Subscribe

Dr Minnema discusses the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma, key data from the MonumenTAL-1 trial, and the importance of designing clinical trials to address unmet patient needs.

Share
Subscribe
Next
Fonkoua Sheds Light on Liver Cancer Clinical Trial Disparities
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air